Immatics Announces $125 Million Underwritten Offering Houston, Texas and Tuebingen, Germany

Immatics Announces $125 Million Underwritten

Texas and Tuebingen, Germany, December 05, 2025 -

Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage

biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000

ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting

discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary

Jefferies, Leerink Partners and Cantor are acting

as joint book-running managers for the offering.

A registration statement relating to the securities

has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on April 3, 2025. The

offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus

supplement and the accompanying prospectus relating to the offering may be obtained free of charge from

This press release shall not constitute an offer

to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction

in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such

state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration

requirements of the Securities Act of 1933, as amended.

Immatics is committed to making a meaningful impact

on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers.

Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities,

spanning TCR T-cell therapies and TCR bispecifics.

Forward-Looking Statements

Certain statements in this press release may be

considered forward-looking statements, including statements regarding the securities offering. Such forward-looking statements are subject

to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such

forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable

by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible

to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include,

but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties

and factors set forth in filings with the SEC. Nothing in this press release should be regarded as a representation by any person that

the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements

will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics

undertakes no duty to update these forward-looking statements.

For more information, please contact: